Cucchetti Alessandro, Zhong Jianhong, Berhane Sarah, Toyoda Hidenori, Shi KeQing, Tada Toshifumi, Chong Charing C N, Xiang Bang-De, Li Le-Qun, Lai Paul B S, Ercolani Giorgio, Mazzaferro Vincenzo, Kudo Masatoshi, Cescon Matteo, Pinna Antonio Daniele, Kumada Takashi, Johnson Philip J
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy; Morgagni - Pierantoni Hospital, Forlì, Italy.
Department of Hepatobiliary Surgery, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, China.
J Hepatol. 2020 Apr;72(4):711-717. doi: 10.1016/j.jhep.2019.11.016. Epub 2019 Nov 30.
BACKGROUND & AIMS: The popular sense of the word "cure" implies that a patient treated for a specific disease will return to have the same life expectancy as if he/she had never had the disease. In analytic terms, it translates into the concept of statistical cure which occurs when a group of patients returns to having similar mortality to a reference population. The aim of this study was to assess the probability of being cured from hepatocellular carcinoma (HCC) by hepatic resection.
Data from 2,523 patients undergoing resection for HCC were used to fit statistical cure models, to compare disease-free survival (DFS) after surgery to the survival expected for patients with chronic hepatitis and/or cirrhosis and the general population, matched by sex, age, race/ethnicity and year of diagnosis.
The probability of resection enabling patients with HCC to achieve the same life expectancy as those with chronic hepatitis and/or cirrhosis was 26.3%. The conditional probability of achieving this result was time-dependent, requiring about 8.9 years to be accomplished with 95% certainty. Considering the general population as a reference, the cure fraction decreased to 17.1%. Uncured patients had a median DFS of 1.5 years. In multivariable analysis, patient's age and the risk of early HCC recurrence (within 2 years) were independent determinants of the chance of cure (p <0.001). The chances of being cured ranged between 36.0% for individuals at low risk of early recurrence to approximately 3.6% for those at high risk.
Estimates of the chance of being cured of HCC by resection showed that cure is achievable, and its likelihood increases with the passing of recurrence-free time. The data presented herein can be used to inform decision making and to provide patients with accurate information.
Data from 2,523 patients who underwent resection for hepatocellular carcinoma were used to estimate the probability that resection would enable treated patients to achieve the same life expectancy as patients with chronic hepatitis and/or cirrhosis, and the general population. Herein, the cure model suggests that in patients with hepatocellular carcinoma, resection can enable patients to achieve the same life expectancy as those with chronic liver disease in 26.3% of cases and as the general population in 17.1% of cases.
“治愈”一词的普遍含义是,接受特定疾病治疗的患者预期寿命将恢复到从未患过该疾病时的水平。从分析角度来看,这转化为统计学治愈的概念,即一组患者的死亡率恢复到与参照人群相似的水平时发生统计学治愈。本研究的目的是评估肝切除治愈肝细胞癌(HCC)的概率。
使用2523例接受HCC切除术患者的数据来拟合统计学治愈模型,将术后无病生存期(DFS)与按性别、年龄、种族/民族和诊断年份匹配的慢性肝炎和/或肝硬化患者及普通人群的预期生存期进行比较。
肝切除使HCC患者达到与慢性肝炎和/或肝硬化患者相同预期寿命的概率为26.3%。实现这一结果的条件概率与时间相关,在95%的确定性水平下大约需要8.9年才能实现。以普通人群作为参照,治愈比例降至17.1%。未治愈患者的DFS中位数为1.5年。在多变量分析中,患者年龄和早期HCC复发风险(2年内)是治愈机会的独立决定因素(p<0.001)。治愈机会在早期复发低风险个体中为36.0%,在高风险个体中约为3.6%。
肝切除治愈HCC的机会估计表明治愈是可以实现的,并且其可能性随着无复发时间的推移而增加。本文所呈现的数据可用于指导决策并为患者提供准确信息。
使用2523例接受肝细胞癌切除术患者的数据来估计肝切除使治疗患者达到与慢性肝炎和/或肝硬化患者以及普通人群相同预期寿命的概率。在此,治愈模型表明,在肝细胞癌患者中,肝切除在26.3%的病例中可使患者达到与慢性肝病患者相同的预期寿命,在17.1%的病例中可使患者达到与普通人群相同的预期寿命。